Celltrion
068270.KS
$178.47
Share price
-1.52%
Change (1 day)
-11.77%
Change (1 year)
Categories
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.
Revenue for Celltrion (068270.KS)
Revenue in 2024 (TTM): A$3.92 Billion
According to Celltrion
's latest financial reports the company's current revenue (TTM 
) is A$4.13 Billion. an increase over the revenue in the year 2023 that were of A$2.42 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Celltrion from 2008 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | A$4.14 B | 71.27% |
| 2023 | A$2.42 B | -6.01% |
| 2022 | A$2.57 B | 13.45% |
| 2021 | A$2.27 B | 9.73% |
| 2020 | A$2.06 B | 49.43% |
| 2019 | A$1.38 B | 9.29% |
| 2018 | A$1.26 B | 16.31% |
| 2017 | A$1.08 B | 35.04% |
| 2016 | A$0.80 B | 12.26% |
| 2015 | A$0.71 B | 30.91% |
| 2014 | A$0.54 B | 136.62% |
| 2013 | A$0.23 B | -24.91% |
| 2012 | A$0.30 B | |
| 2010 | A$0.15 B | 19.04% |
| 2009 | A$0.12 B | 27.13% |
| 2008 | A$0.10 B |